Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC.

Trial Profile

Randomized, Open-label, phase3 Trial Comparing Amrubicin Combined With Cisplatin Versus Etoposide-Cisplatin as First-line Treatment in Patients With Extensive Disease SCLC.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2016

At a glance

  • Drugs Amrubicin (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2013 Preliminary results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Sep 2012 Data from this trial was used in support of an imported drug registration application cancer in China for amrubicin to the State Food and Drug Administration for the treatment of small cell lung cancer on 21 August 2012.
    • 05 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top